Looking back and looking ahead: A momentous (and misguided) time for drug pricing policy
- Aug 15
Incubate responds to Maximum Fair Prices for first 10 drugs selected for Medicare price controls
- Jun 13
Incubate Launches Life Science Investment Tracker to Analyze Impact of the Inflation Reduction Act
- Feb 7
Incubate Submits Letter On HELP Committee Hearing
- Feb 1
Life Sciences Investors Applaud Bipartisan Bill To Eliminate Small-Molecule Penalty
- Dec 7, 2023
Life Sciences Investors React To Biden Administration’s March-In Decision
- Nov 20, 2023
What Is Up For Biopharmaceutical Policy In 2024?
- Oct 12, 2023
Mary R. Grealy On The Small Molecule Penalty, U.S. Dominance In Life Sciences, And More
- Sep 26, 2023
Incubate Releases Statement On Fitch Ratings’ Analysis Of Medicare Drug Price Negotiations
- Aug 29, 2023
Life Sciences Investors React To First 10 Drugs Selected For Government Price Controls
- Jul 10, 2023
Incubate Submits Comment In Response To Draft Legislation To Reauthorize PAHPA
- May 22, 2023
Massachusetts Biotech Community Calls On Congress To Fix The Small Molecule Penalty
- Apr 17, 2023
Incubate Submits Comment To CMS Regarding Its Draft Guidance For The Medicare Drug Price Negotiation Program
- Sep 23, 2022
The Inflation Reduction Act: Implications For Biopharma Companies And Patients
- Aug 6, 2022
Incubate Statement On Amendment 5284 Of The Inflation Reduction Act
- Jun 30, 2022
Incubate Statement On WTO Decision To Suspend Global IP Rights
- May 25, 2022
Incubate Comment In Response To The FTC’s Request For Comments On The Business Practices Of PBMs